G. Walmsley Graham - 28 Jul 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
28 Jul 2023
Net transactions value
+$2,362,234
Form type
4
Filing time
01 Aug 2023, 19:52:10 UTC
Previous filing
27 Jun 2023
Next filing
10 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Purchase $1,280,709 +30,000 +5.8% $42.69 550,000 28 Jul 2023 See Footnote F1
transaction AKRO Common Stock Purchase $1,081,525 +25,000 +4.5% $43.26 575,000 01 Aug 2023 See Footnote F1
holding AKRO Common Stock 2,168 28 Jul 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.